Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 GeneticVariation disease BEFREE Regarding safety, compared with patients who did not receive mTOR inhibitors, those who did had a higher risk of suffering stomatitis (RR = 3.20, 95% CI = 1.49,6.86, P = 0.003). 30760308 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 Biomarker disease BEFREE Prophylactic use of steroid mouth rinse provides a cost-effective option that substantially decreases the incidence and severity of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis and related oral AEs as well as the need for dose modification in MBC patients undergoing treatment with an mTOR inhibitor. 30833486 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 Biomarker disease BEFREE Mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis (mIAS) is a common adverse event (AE), secondary to mTOR inhibitor therapy, that can have a negative impact on treatment adherence, quality of life, and health care costs. 29439772 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 Biomarker disease BEFREE A common class-specific toxicity of mammalian target of rapamycin (mTOR) inhibitors is stomatitis. 29547614 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 GeneticVariation disease BEFREE Of the oral mucosal toxicities observed with targeted therapies, oral mucositis is the most frequent with mammalian target of rapamycin (mTOR) inhibitors, followed by stomatitis associated to multikinase angiogenesis and HER inhibitors, geographic tongue, oral hyperkeratotic lesions, lichenoid reactions, and hyperpigmentation. 30374901 2018
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 Biomarker disease BEFREE Oral mucosal toxicities described in this review include mTOR inhibitor-associated stomatitis (mIAS); stomatitis, benign migratory glossitis, and osteonecrosis of the jaw associated with multi-targeted kinase inhibitors of the VEGF and PDGF receptors; mucositis induced by EGFR inhibitors (in monotherapy or in combination with head and neck radiotherapy and/or chemotherapy); hyperkeratotic lesions with BRAF inhibitors; pigmentary changes and lichenoid reactions secondary to imatinib; and more recent data on the "Osler-Weber-Rendu-like syndrome" described with the antibody-drug conjugate, TDM-1. 28224235 2017